Company intelligence / Profile preview

Karos Partners

New Haven, Connecticut, United Stateskarohealthcare.com ↗

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Karos Pharmaceuticals developed small molecule therapeutics targeting peripheral serotonin synthesis. Its lead program, KAR5585, completed Phase 1 trials for pulmonary arterial hypertension. Additional research included preclinical work on related rare and orphan disease indications. The company was acquired in August 2017.

Therapeutic areas: Metabolic DisordersOncologyPulmonologyImmunologyRheumatologyCardiovascular
Modalities: small molecules (e.g., TPH1 inhibitors)
Industry: Biotech

Beyond the preview

Go deeper on Karos Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Karos Partners.

Explore the full profile